Linaclotide in the treatment of patients with irritable bowel syndrome and constipation: analysis of an opportunity
Linaclotide is a secretagogue that provides a combined effect on visceral pain. The European Medicines Agency has authorized its indication for the symptomatic treatment of moderate to severe irritable bowel syndrome with constipation in adults. The purpose of this review is to discuss the clinical...
Main Author: | Fernando Carballo |
---|---|
Format: | Article |
Language: | English |
Published: |
Aran Ediciones
2013-06-01
|
Series: | Revista Espanola de Enfermedades Digestivas |
Subjects: | |
Online Access: | http://scielo.isciii.es/scielo.php?script=sci_arttext&pid=S1130-01082013000600006&lng=en&tlng=en |
Similar Items
-
Resultados a largo plazo del tratamiento con linaclotida en el síndrome de intestino irritable tipo estreñimiento
by: Fernando Geijo-Martínez, et al. -
Diagnosis and treatment of irritable bowel syndrome with predominant constipation in the primary-care setting: focus on linaclotide
by: Chandar AK
Published: (2017-10-01) -
Consumo de fibra dietaria, por día, en niños con estreñimiento funcional y síndrome de intestino irritable
by: Ingrith Viviana Hoyos-García, et al.
Published: (2019-01-01) -
IL-10 and TNF-α polymorphisms in subjects with irritable bowel syndrome in Mexico
by: Max Schmulson, et al.
Published: (2013-08-01) -
The use of probiotics in gastrointestinal diseases
by: Daniel Cisternas
Published: (2011-06-01)